Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BSTCNASDAQ:BYSIOTCMKTS:EMISNASDAQ:FLXNNASDAQ:STSA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSTCBioSpecifics Technologies$88.53$88.47$42.00▼$89.15$650.25M0.2461,105 shsN/ABYSIBeyondSpring$1.80-2.7%$2.33$0.65▼$4.00$70.06M0.15192,492 shs55,502 shsEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/AFLXNFlexion Therapeutics$9.12$9.20$4.30▼$13.66$458.93M1.531.18 million shsN/ASTSASatsuma Pharmaceuticals$1.10-0.9%$1.08$0.59▼$8.08$36.47M0.1701,788 shs1.83 million shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSTCBioSpecifics Technologies0.00%0.00%0.00%0.00%0.00%BYSIBeyondSpring+2.78%-18.14%-35.76%+105.56%+36.03%EMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%FLXNFlexion Therapeutics0.00%0.00%0.00%0.00%0.00%STSASatsuma Pharmaceuticals0.00%0.00%0.00%0.00%+8.91%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ABYSIBeyondSpring0.0033 of 5 stars0.00.00.00.00.02.50.0EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASTSASatsuma PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSTCBioSpecifics TechnologiesN/AN/AN/AN/ABYSIBeyondSpringN/AN/A$1.25-30.56% DownsideEMISEmisphere TechnologiesN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/ASTSASatsuma PharmaceuticalsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSTCBioSpecifics Technologies$38.19M17.03$3.38 per share26.18$18.42 per share4.81BYSIBeyondSpring$1.35M51.89N/AN/A($0.36) per share-5.00EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AFLXNFlexion Therapeutics$85.55M5.36N/AN/A($0.34) per share-26.82STSASatsuma PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSTCBioSpecifics Technologies$24.47M$3.3337.5117.60N/A47.43%14.81%14.46%N/ABYSIBeyondSpring-$33.28MN/A0.00∞N/AN/AN/AN/A4/18/2024 (Estimated)EMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AFLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/ASTSASatsuma Pharmaceuticals-$70.06M-$2.01N/AN/AN/AN/A-115.24%-102.26%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/ASTSASatsuma PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSTCBioSpecifics TechnologiesN/A66.2466.24BYSIBeyondSpringN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AFLXNFlexion TherapeuticsN/A4.384.05STSASatsuma PharmaceuticalsN/A7.447.44OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSTCBioSpecifics Technologies60.34%BYSIBeyondSpring40.29%EMISEmisphere TechnologiesN/AFLXNFlexion Therapeutics90.01%STSASatsuma Pharmaceuticals93.26%Insider OwnershipCompanyInsider OwnershipBSTCBioSpecifics Technologies15.70%BYSIBeyondSpring29.31%EMISEmisphere Technologies72.90%FLXNFlexion Therapeutics9.13%STSASatsuma Pharmaceuticals31.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBSTCBioSpecifics Technologies77.35 millionN/ANot OptionableBYSIBeyondSpring7338.92 million27.52 millionOptionableEMISEmisphere Technologies6N/AN/ANot OptionableFLXNFlexion Therapeutics25750.32 million45.73 millionOptionableSTSASatsuma Pharmaceuticals2133.15 million22.81 millionNot OptionableBYSI, STSA, BSTC, FLXN, and EMIS HeadlinesSourceHeadlineWith manufacturing-related rejection, FDA turns its nose up at Satsuma's migraine nasal sprayfiercepharma.com - January 18 at 8:54 PMSatsuma City High Schoolusnews.com - August 30 at 5:25 PMJapanese pharma acquires its crash-strapped Durham spin-outbizjournals.com - June 9 at 3:18 PMJapanese pharma acquires its Durham spin-outbizjournals.com - June 8 at 4:49 PMSatsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migrainefinance.yahoo.com - May 18 at 8:06 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TESS, STSA, CHRAmarketwatch.com - May 3 at 5:56 PMShareholder Alert: Ademi LLP investigates whether Satsuma Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Shin Nipponbenzinga.com - May 1 at 8:34 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NATI, RXDX, STSA, CHRAmarketwatch.com - April 25 at 4:05 PMSTSA Satsuma Pharmaceuticals, Inc.seekingalpha.com - April 22 at 6:34 PMSatsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meetingfinance.yahoo.com - April 21 at 10:22 AMAfter Satsuma Pharma Rockets 65% on SNBL Bid, There Could Still Be 6X More Upsidemsn.com - April 19 at 12:39 AMSatsuma Pharmaceuticals Shares Soar on Shin Nippon Biomedical Deal >STSAmarketwatch.com - April 18 at 1:38 AMSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Satsuma Pharmaceuticals, Inc. Buyoutbenzinga.com - April 17 at 3:37 PMPeninsula company bets big part of potential $221M sale on future of migraine drugbizjournals.com - April 17 at 3:37 PMSTSA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Satsuma Pharmaceuticals, Inc. Is Fair to Shareholdersmarkets.buffalonews.com - April 17 at 10:36 AMSatsuma Pharma Agrees To Be Acquired By Shin Nippon Biomedicalmarkets.businessinsider.com - April 17 at 10:36 AMSatsuma Skyrockets after Acquisition by Shin Nipponmsn.com - April 17 at 10:36 AMWhy Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today?investorplace.com - April 17 at 9:09 AMSNBL to Acquire Satsuma Pharmaceuticalsfinance.yahoo.com - April 16 at 11:18 PMH.C. Wainwright Reaffirms Their Buy Rating on Satsuma Pharmaceuticals (STSA)markets.businessinsider.com - March 30 at 10:15 AMWe're A Little Worried About Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Ratefinance.yahoo.com - March 30 at 10:15 AMMigraine drug maker seeks FDA approval and a partner as it cuts jobsbizjournals.com - March 29 at 1:49 PMSatsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlightsfinance.yahoo.com - March 28 at 6:05 PM8-K: Satsuma Pharmaceuticals, Inc.marketwatch.com - February 18 at 2:42 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBioSpecifics TechnologiesNASDAQ:BSTCBioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.BeyondSpringNASDAQ:BYSIBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.Emisphere TechnologiesOTCMKTS:EMISEmisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Flexion TherapeuticsNASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.Satsuma PharmaceuticalsNASDAQ:STSASatsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.